ACHIEVEMENTS
ANZUP ANNUAL REPORT 2022
Grants and Awards Infrastructure Grants Funds provided by Cancer Australia to support ANZUP’s infrastructure up until December 2021 were managed by the University of Sydney and not reported in the financial accounts of ANZUP unless transferred in support of specific expenses incurred by ANZUP. In January 2022 ANZUP was successful in our 2022-2024 Support for Cancer Clinical Trials grant application and ANZUP will administer this grant. Other Grants/ Funding during the 2021-22 period are outlined below.
BL.12: A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen. Funding by NCIC Clinical Trials Group AUD$1,384,662, Specialised Therapeutics AUD$250,000 (2015-2018). During this reporting period $12,018.72 was transferred to ANZUP.
Infrastructure Funding
DASL-HiCaP: A randomised phase III double-blind, placebocontrolled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. Funding by Bayer USD$53,173,088. During this period USD$485,455 was transferred to ANZUP and reported in the annual accounts.
Cancer Australia Infrastructure Grant: 1 July 2018 to 30 December 2021, AUD$1,750,000 awarded to ANZUP and our collaborator, The University of Sydney. During this reporting period AUD$125,000 was transferred to ANZUP and is reported in the Annual Accounts.
ENZAMET: A randomised phase III trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer. Funding by Astellas AUD$19,962,490 (2014-2022). During this reporting period USD$94,910 was transferred to ANZUP and was reported in the annual accounts.
ANZUP was also successful in applying for the 2022-2024 Cancer Australia Infrastructure Grant and was awarded $1,250,000 for the next 3 years. During this reporting period ANZUP received AUD$260,000 and is reported in the Annual Accounts.
ENZAMET Translational Research Program: During this reporting period US$110,000 was transferred to ANZUP for TR Execution Milestone Direct Costs and was reported in the annual accounts
Research Grants Funds provided by Cancer Australia, the National Health and Medical Research Council, philanthropic funding bodies and pharmaceutical companies in support of ANZUP trials managed by the University of Sydney, are not reported in ANZUP’s financial accounts. Funds to support ANZUP sponsored trials and site payments, insurance and other trial related costs are transferred to ANZUP and are reflected in these accounts. ANZUP grant income and expenditure during this reporting period are included in the 2020/2021 financial accounts. Grants awarded to ANZUP Cancer Trials Group during this reporting period are listed below: BCGMM: Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a 2-stage, randomised phase 3 trial. Funding by NHMRC AUD$ $1,587,163.80. (2019 – 2023). AUD$22,500 was transferred to ANZUP and reported in the annual accounts.
ENZA-p: A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration resistant prostate cancer treated with enzalutamide. Funding by Prostate Cancer Research Alliance: The Australian Government and Movember Foundation Collaboration AUD$4,000,000; Endocyte USD$320,000; St Vincent’s Clinic Foundation AUD$400,000; GenesisCare AUD$300,000; and Roy Morgan Research Ltd AUD$300,000; (2020-2024). During this reporting period AUD$1,154,037 was transferred to ANZUP and was reported in the annual accounts. ENZARAD: A randomised phase III trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer. Funding by Astellas AUD$13,184,412 (2014-2022). During this reporting period no funds were transferred to ANZUP.
33
